Theriva puts GvHD drug on backburner to focus on oncolytic adenovirus
Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change up in its R&D focus.
Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change up in its R&D focus.
